N-Butyl-N'-cyclopropyl ethylenediamine | 886503-53-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-Butyl-N'-cyclopropyl ethylenediamine
• 英文别名: N-butyl-N'-cyclopropylethane-1,2-diamine
• CAS: 886503-53-3
• 化学式: C₉H₂₀N₂
• 分子量: 156.27
• InChiKey: XBRFPLKTKVWZJH-UHFFFAOYSA-N

物化性质

• 沸点：
  226.4±8.0 °C(Predicted)
• 密度：
  0.89±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE
  申请人：Ortega Muñoz Alberto

  公开号：US20120283266A1

  公开（公告）日：2012-11-08

  The invention relates to a compound of Formula (I): (A′) x -(A)-(B)-(Z)-(L)-(D), wherein: (A) is heteroaryl or aryl; each (A′), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A′) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, aryl, arylalkoxy, alkyl, alkoxy, cyano, sulfonyl, amido, and sulfinyl; X is 0, 1, 2, or 3; (B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B); (Z) is —NH—; (L) is chosen from —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, and —CH 2 CH 2 CH 2 CH 2 —; and (D) is chosen from —N(—R1)—R2, —O—R3, and —S—R3, wherein: R1 and R2 are mutually linked to form a heterocyclic ring together with the nitrogen atom that R1 and R2 are attached to, wherein said heterocyclic ring has 0, 1, 2, or 3 substituents independently chosen from —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl)(C 1 -C 6 alkyl), alkyl, halo, cyano, alkoxy, haloalkyl, and haloalkoxy, or R1 and R2 are independently chosen from —H, alkyl, cycloalkyl, haloalkyl, and heterocyclyl, wherein the sum of substituents on R1 and R2 together is 0, 1, 2, or 3, and the substituents are independently chosen from —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl)(C 1 -C 6 alkyl), and fluoro; and R3 is chosen from —H, alkyl, cycloalkyl, haloalkyl, and heterocyclyl, wherein R3 has 0, 1, 2, or 3 substituents independently chosen from —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl)(C 1 -C 6 alkyl), and fluoro; or an enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt or solvate thereof. The compounds of the invention show inhibitory LSD1 activity, which makes them useful in the treatment or prevention of diseases such as cancer.

  本发明涉及一种化合物，其化学式为(I):(A′)x-(A)-(B)-(Z)-(L)-(D)，其中：(A)为杂环芳基或芳基；每个(A′)，如果存在，则独立选择自芳基、芳基烷氧基、芳基烷基、杂环芳基、芳基氧基、卤、烷氧基、卤代烷基、环烷基、卤代烷氧基和氰，其中每个(A′)均被取代为0、1、2或3个取代基，所述取代基独立选择自卤、卤代烷基、芳基、芳基烷氧基、烷基、烷氧基、氰、磺酰基、酰胺和亚磺酰基；X为0、1、2或3；(B)为环丙基环，其中(A)和(Z)与(B)的不同碳原子共价键合；(Z)为—NH—；(L)选择自—CH2CH2—、—CH2CH2CH2—和—CH2CH2CH2CH2—；(D)选择自—N(—R1)—R2、—O—R3和—S—R3，其中：R1和R2与氮原子一起互相连接形成一个杂环环，所述杂环环具有0、1、2或3个取代基，所述取代基独立选择自—NH2、—NH(C1-C6烷基)、—N(C1-C6烷基)(C1-C6烷基)、烷基、卤、氰、烷氧基、卤代烷基和卤代烷氧基，或R1和R2独立选择自—H、烷基、环烷基、卤代烷基和杂环芳基，其中R1和R2的取代基总和为0、1、2或3，所述取代基独立选择自—NH2、—NH(C1-C6烷基)、—N(C1-C6烷基)(C1-C6烷基)和氟；R3选择自—H、烷基、环烷基、卤代烷基和杂环芳基，其中R3具有0、1、2或3个取代基，所述取代基独立选择自—NH2、—NH(C1-C6烷基)、—N(C1-C6烷基)(C1-C6烷基)和氟；或其对映体、顺反异构体或混合物，或其药学上可接受的盐或溶剂。本发明的化合物显示出抑制LSD1活性，因此它们在治疗或预防癌症等疾病方面非常有用。